AntibodyCurated CoreFDAstaleRegeneronApproved
linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt)
Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody · BCMA × CD3
#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 24Status Approved